Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study.
Courtney D Di NardoStéphane de BottonDaniel A PollyeaRichard M StoneJessica K AltmanAmir T FathiTharin LimsakunMin LiangSung ChoeMohammad HossainAdriana E TronQian MengStephanie M KapsalisShuchi S PandyaEytan M SteinPublished in: American journal of hematology (2023)